Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
Clinical trial NCT04697953 · WITHDRAWN
Trial details
- NCT number
- NCT04697953
- Sponsor
- Novartis Pharmaceuticals
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-31
- Primary completion
- 2021-06-21
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.